RepligenRGEN +9.50%83 EBITDA Margin % is 16.42% as of Mar. 2026, which is 28% below its 10-year median of 22.81. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Repligen ranks better than 81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Repligen's EBITDA for the
three
months ended in Mar. 2026 was $31.9 Mil. Repligen's Revenue for the
three
months ended in Mar. 2026 was $194.3 Mil. Therefore, Repligen's EBITDA margin for the quarter that ended in Mar. 2026 was 16.42%.
Repligen (NAS:RGEN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Repligen EBITDA Margin % Related Terms
Repligen EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Repligen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGEN vs ATR, AVTR, TFX: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Repligen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Repligen's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen (RGEN) has a EBITDA Margin % of 16.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Repligen and its competitors. This is 28% below median its historical median of 22.81. Over the past decade, Repligen's EBITDA Margin % has ranged from 12.65 to 34.60. According to the industry distribution chart, Repligen ranks #155 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 19%.
Is Repligen's EBITDA Margin % too high?
Repligen's current EBITDA Margin % of 16.42% is 28% below median its 10-year median of 22.81. Over the past 10 years, this metric has ranged from a low of 12.65 to a high of 34.60. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Repligen's value of 16.42% is 119.7% above this industry median. Based on the distribution chart, Repligen ranks #155 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's EBITDA Margin % compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #155 out of 816 companies for EBITDA Margin %. This places Repligen in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Repligen's value of 16.42% is 119.7% above this benchmark. Historically, Repligen's own EBITDA Margin % has ranged from 12.65 to 34.60 over the past decade. While the company's 10-year median is 22.81 vs. the industry median of 7.48, Repligen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current EBITDA Margin % of 16.42% is 119.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current EBITDA Margin % is 16.42%, which is 28% below median its own 10-year median of 22.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.40 — trading 21.3% below its estimated fair value. The current EBITDA Margin % is 16.42%, which is 28% below median its 10-year median of 22.81 and 119.7% above the Medical Devices & Instruments industry median of 7.48. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Repligen (RGEN), the current EBITDA Margin % is 16.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $138.40 is trading 21.3% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
EBITDA Margin %: 16.42% (28% below median its 10-year median of 22.81)
GF Value™: $175.89 vs. price of $138.40 (21.3% below fair value)
Industry Position: 119.7% above the Medical Devices & Instruments median (#155 of 816)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
